Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab and Umbralisib (U2) in CLL (UNITY-CLL)
NCT02612311Phase 3Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Nov 2015
- Primary completion
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of ublituximab and umbralisib in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc. Started Nov 2015; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02612311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612311.